Medical Condition News

RSS

New technology allows faster and more accurate diagnosis of brain aneurysm

Preventing deadly ruptures of the blood vessels in the brain is the aim of a new Mayo Clinic project to help radiologists detect aneurysms with far greater speed and accuracy.

27 Jan 2010

Researchers identify new drugs to protect brain cells from neurological disease

Researchers have identified a compound that mimics one of the brain's own growth factors and can protect brain cells against damage in several animal models of neurological disease.

27 Jan 2010

USAN approves generic name "ulimorelin" for Tranzyme Pharma's TZP-101

Tranzyme Pharma today announced that the United States Adopted Name Council (USAN) has approved the generic name “ulimorelin” for Tranzyme’s novel, late-stage, prokinetic agent TZP-101. Ulimorelin, if approved, is expected to be a first-in-class drug for the treatment of gastrointestinal (GI) dysmotility indications in acute care (hospital-based) settings.

27 Jan 2010

Findings provide new insight into factors causing neurodegenerative diseases

Scientists at the Babraham Institute have discovered a novel survival factor whose rapid transport along nerve cells is crucial for keeping them alive. The same factor seems likely to be needed to keep our nerves healthy as we age.

27 Jan 2010

Mayo Clinic teams up with PCH to provide surgical treatment for patients with PE

Mayo Clinic is teaming up with Phoenix Children's Hospital (PCH) and Pediatric Surgeons of Phoenix to provide comprehensive surgical treatment to both children and adults with pectus deformities.

27 Jan 2010

Research could help develop sophisticated treatments for Type I diabetes

New research that significantly improves our understanding of how insulin interacts with cells in the human body is published today.

27 Jan 2010

Study sheds light on cellular communication systems involved in neurodegenerative, cancer and cardiovascular diseases

Cells rely on a range of signaling systems to communicate with each other and to control their own internal workings. Scientists from the European Molecular Biology Laboratory (EMBL) in Hamburg, Germany, have now found a way to hack into a vital communications system, raising the possibility of developing new drugs to tackle disorders like neurodegeneration, cancer and cardiovascular disease.

27 Jan 2010

Tel Aviv University expert reviews environmental triggers of common autoimmune diseases

The links between autoimmune diseases, infections, genetics and the environment are complex and mysterious. Why are people who live near airports more susceptible to autoimmune diseases like rheumatoid arthritis and lupus? How do hormones in meat trigger the onset of a disease?

27 Jan 2010

Geron collaborates to explore hESC-based product for Alzheimer’s disease

Geron Corporation today announced that it has entered into a collaboration jointly funded by Geron and a University of California Discovery Research and Training Grant to investigate the therapeutic potential of its human embryonic stem cell (hESC)-based product, GRNOPC1, for Alzheimer’s disease. The company is currently developing GRNOPC1 for the potential treatment of spinal cord injury.

27 Jan 2010

Antioxidants can also harm

Antioxidants increasingly have been praised for their benefits against disease and aging, but recent studies at Kansas State University show that they also can cause harm.

27 Jan 2010

Biomoda applauds Senator for introducing legislative bill for lung cancer screening

Cancer diagnostics company Biomoda, Inc. (www.biomoda.com) today applauded Nebraska State Sen. Bob Krist and his co-sponsors for introducing legislation to screen up to 500 Nebraska veterans for early-stage lung cancer.

27 Jan 2010

Counterfeit version of Alli sold over the Internet: FDA warns

FDA is alerting consumers to an unsafe, counterfeit version of the weight-loss drug Alli sold over the Internet.

27 Jan 2010

Potential risk factors in skipping insulin injections

More than half of people with diabetes who take insulin injections to control their diabetes say they have intentionally skipped an injection, with one-fifth of them reporting that they do so "sometimes" or "often," according to a study being published this month in Diabetes Care.

27 Jan 2010

Musculoskeletal injuries more prevalent among female athletes

Female athletes experience dramatically higher rates of specific musculoskeletal injuries and medical conditions compared to male athletes, according to exercise physiologist Vicki Harber in the Faculty of Physical Education and Recreation at the University of Alberta.

27 Jan 2010

Cinergy Health creates five steps to reduce childhood obesity

Cinergy Health, a nationwide health insurance agency providing guaranteed issue and short term major medical insurance programs, responds to the alarming rise in childhood obesity. One in three children in America is overweight or obese and one out of every five teenagers has a cholesterol level that increases the risk of heart disease.

27 Jan 2010

Study: PROSTVAC-VF vaccine effective in treating patients with metastatic prostate cancer

In a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to spur an immune system attack on prostate tumor cells lived substantially longer than patients who received a placebo vaccine, report researchers at Dana-Farber Cancer Institute and affiliated organizations.

27 Jan 2010

Update on Cardium Therapeutics' plans for commercial development of Generx

Cardium Therapeutics reported today that its Cardium Biologics division provided an update on plans for the continuing commercial development of Generx™ (alferminogene tadenovec, Ad5FGF-4), a DNA-based angiogenic therapy product candidate for patients with coronary artery disease.

27 Jan 2010

U.S. court decision favors Teva in generic Temodar ANDA litigation

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Schering-Plough’s brain tumor treatment Temodar® (temozolomide). The Court found that U.S. Patent No. 5,260,291 is not enforceable due to prosecution laches and inequitable conduct.

27 Jan 2010

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Patients with gastrointestinal stromal tumours (GIST) can now take action at an earlier stage of this rare form of cancer to reduce the risk of their disease returning following surgery. Novartis Pharmaceuticals Canada announced today that Gleevec* (imatinib mesylate) has received conditional approval by Health Canada for the adjuvant (post-surgical) treatment of adult patients who are at intermediate to high risk of disease recurrence following the surgical removal of GIST.

27 Jan 2010

Resveratrol supplements may offer potential benefits for cancer patients

For years, consumers and natural health advocates have been convinced of the benefits of resveratrol, the healthy by-product of red-wine grapes, but recently, the National Cancer Institute decided it was time to investigate further.

27 Jan 2010